249 filings
Page 7 of 13
8-K
gb1eqtlafgndlo0hw 0z
3 Mar 15
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial and Operational Results
12:00am
8-K
ahovu ajt410o
12 Feb 15
Entry into a Material Definitive Agreement
12:00am
8-K
247jy
7 Jan 15
Departure of Directors or Certain Officers
12:00am
8-K
ku29sw juiomy
12 Nov 14
Other Events
12:00am
8-K
746gny4gm1
3 Nov 14
Results of Operations and Financial Condition
12:00am
8-K
k6bz65hb rd3hglo4he3
9 Oct 14
Other Events
12:00am
8-K
yeh7b2p
22 Sep 14
Other Events
12:00am
8-K
2n8x7
1 Aug 14
Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
12:00am
8-K
9lz 4nlfyn8g
2 Jun 14
Threshold Announces Data from Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (AvastinĀ®) in Patients with Recurrent Glioblastoma
12:00am
8-K
uwh5xl
21 May 14
Departure of Directors or Certain Officers
12:00am
8-K
kprs8tc8uzy1 04m7uly
1 May 14
Threshold Pharmaceuticals Reports First Quarter 2014 Financial and Operational Results
12:00am
8-K
1f1nzmjoo6 z2wt6m410
6 Mar 14
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
12:00am
8-K
f1boaaoqbmzwlfk1aqta
2 Jan 14
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma
12:00am
8-K
a14j9r p0bvi
11 Dec 13
Other Events
12:00am
8-K
hp8wyjk1gifxl 3s
4 Nov 13
Threshold Pharmaceuticals Reports Third Quarter 2013 Financial and Operational Results
12:00am
8-K
gbba53qvbtyj
22 Oct 13
Other Events
12:00am
8-K/A
h71c5ehuwr 0p
30 Sep 13
Submission of Matters to a Vote of Security Holders
12:00am
8-K
pc97rfg
1 Aug 13
Threshold Pharmaceuticals Reports Second Quarter 2013 Financial and Operational Results
12:00am
8-K
ieu46wf
1 Jul 13
Other Events
12:00am
8-K
zr5ohhf
3 Jun 13
Other Events
12:00am